WaveMan
WaveMan · Company
SCYX · Scynexis Inc
> Search tickers & screens ⌘K
LIVE
← All companies

SCYX Scynexis (SCYX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001178253
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
12
13F, latest reported quarter

Scynexis insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for SCYNEXIS INC in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Angulo Gonzalez David
Chief Executive Officer
BUY
2026-04-02 SECtraded 2026-04-01
108,695
-
-48.1%
Angulo Gonzalez David
Chief Executive Officer
BUY
2024-09-16 SECtraded 2024-09-12
20,000
$27.4K
-70.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 3.9% of the 507,871 shares held after it.
  • No other insider bought within 30 days.
  • 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Angulo Gonzalez David bought about $27.4K of SCYX on Sep 12, 2024, the largest insider purchase at the company since 2022; 12 funds added in the latest 13F quarter.
Taglietti Marco
Chief Executive Officer
BUY
2022-04-28 SECtraded 2022-04-26
75,000
$225.0K
-82.2%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 27.6% of the 272,068 shares held after it.
  • 1 other insider bought within 30 days.
  • 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Taglietti Marco bought about $225.0K of SCYX on Apr 26, 2022, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 12 funds added in the latest 13F quarter.
Sukenick Scott
General Counsel
BUY
2022-04-28 SECtraded 2022-04-26
3,500
$10.5K
-82.2%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 6.5% of the 53,499 shares held after it.
  • 1 other insider bought within 30 days.
  • 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel Sukenick Scott bought about $10.5K of SCYX on Apr 26, 2022, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 12 funds added in the latest 13F quarter.
4 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
12 funds bought in last quarter
below 79% of Pharma & Biotech
Revenue
+449.9% year over year
more than 93% of Pharma & Biotech
Margin
-41.8% net margin
more than 51% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
5.7% of the float short (float per yahoo 2026-10-27) · 2.3 days to cover · settled 2026-10-15
below 53% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch SCYX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-38.1%12M
-42%-13%+15%+44%2025-102025-122026-022026-042026-062026-082026-10 2026-04-01 · Angulo Gonzalez David bought -
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns SCYX: institutional holders (13F)

13F holdings, latest reported quarter
GREAT POINT PARTNERS LLC
944,292 sh
$3.8M
Squadron Capital Management LLC
756,884 sh
$3.1M
ADAGE CAPITAL PARTNERS GP, L.L.C.
543,478 sh
$2.2M
Propel Bio Management, LLC
543,478 sh
$2.2M
Woodline Partners LP
387,520 sh
$1.6M

Congress trades in SCYX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

SCYX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

SCYX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Victory Extended Market Index Fund
$5.3K position · as of 2026-07-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$521.8K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$178.4K position · as of 2026-05-31
0.0%
U.S. MICRO CAP PORTFOLIO
$23.4K position · as of 2026-07-31
0.0%
U.S. VECTOR EQUITY PORTFOLIO
$11.0K position · as of 2026-07-31
0.0%
Dimensional U.S. Small Cap ETF
$25.1K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
10 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
0 active
2
Phase 2
0 active
5
Phase 3
0 active
1
Not applicable
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Government contracts
Award ceilings over the contract's life, subsidiaries included. Not annual revenue (USASpending.gov).
Department Of Health And Human Services
ADVANCE THE DEVELOPMENT OF SCY-247, A NOVEL ANTIFUNGAL CURRENTLY IN PHASE 1 CLINICAL TRIALS, FOR THE · 2026-09-15
$18.5M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 12 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

SCYX financials

Revenue growth
+449.9%
XBRL, annual
Net margin
-41.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$19.2M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-53.3%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$13.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.52x
LongTermDebt as filed 2023-03-31 (39 months older than the period end) (includes the current portion); equity 2026-06-30
Cash flow to debt
-0.38x
TTM operating cash flow over LongTermDebt as filed 2023-03-31 (39 months older than the period end) (includes the current portion)
Return on equity
-18.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-15.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-38.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
13.14x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$62.1M
market value at close 2026-10-26 on 2026-08-01 shares, plus LongTermDebt as filed 2023-03-31 (39 months older than the period end) (includes the current portion), minus cash 2026-06-30
FCF yield
-35.1%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$20.6M$3.7M$140.1M$5.1M
Operating income-$16.1M-$37.1M$72.7M-$85.8M
Net income-$8.6M-$21.3M$67.0M-$62.8M
EPS (diluted)-0.17-0.441.39-1.47
Operating cash flow-$5.3M-$24.0M$60.2M-$79.9M
Cash$21.3M$16.1M$34.0M$45.8M
SEC XBRL, fiscal years, as known on 2026-10-28

SCYX Stock Sonar score 5/7 axes

Find similar shapesCompare

SCYX ranks highest on growth (93rd percentile) and risk and compliance (69th), and lowest on institutional and government (30th), among Pharma & Biotech peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
68
Inputs
  • Return on equity-18.4% · 73 pct, sector of 545
  • Return on assets-15.1% · 71 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-38.0% · 61 pct, sector of 576
Financial health
46
Inputs
  • Debt to equity0.52x · 31 pct, sector of 352
  • Cash flow to debt-0.38x · 61 pct, sector of 371
Growth
93
Inputs
  • Revenue growth, YoY+449.9% · 93 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
30
Inputs
  • Funds adding, latest quarter12 · 21 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180d$18.5M · 40 pct, universe of 69
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
69
Inputs
  • Short interest, % of float+5.7% · 55 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+4.7% · 84 pct, sector of 511
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies